

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/092924 A3

(51) International Patent Classification:

C07K 14/82 (2006.01) **A61K 48/00** (2006.01)
C12N 15/11 (2006.01) **C12N 5/10** (2006.01)
C12N 15/63 (2006.01)

(21) International Application Number:

PCT/US2005/006396

(22) International Filing Date:

24 February 2005 (24.02.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/547,328 24 February 2004 (24.02.2004) US

(71) Applicants (for all designated States except US):

THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION [US/US]; Technology Transfer Office, 4770 Buford Hwy (K79), Atlanta, GA 30341 (US). **VANDERBILT UNIVERSITY** [US/US]; Office of Technology Transfer and Enterprise Development, Vanderbilt University, 1207 17th Avenue South, Suite 105, Nashville, TN 37212 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HODGE, Thomas, W.** [US/US]; 9115 Twelvestones Dr., Roswell, GA 30076 (US). **MCDONALD, Natalie, J.** [US/US]; 2333 Ewing Drive NE, Atlanta, GA 30319-3929 (US). **RUBIN, Donald** [US/US]; 112 Harding Hill Lane, Nashville, TN 37215 (US). **SHAW, Michael, W.** [US/US]; 2614 Willow Cove, Decatur, GA 30033-2200 (US). **SANCHEZ, Anthony** [US/US]; 1717 Red Fox Run, Lilburn, GA 30047 (US). **MURRAY, James, L.** [US/US]; 1260 Park Creek Circle, Lawrenceville, FL 30044 (US).

(74) Agent: **RYBAK, Sheree, Lynn**; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

11 May 2006

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 49/2005 of 8 December 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RAB9A, RAB11A, AND MODULATORS THEREOF RELATED TO INFECTIOUS DISEASE

(57) Abstract: Disclosed herein are methods of reducing infection of a cell by a pathogen, comprising decreasing activity of Rab9A or Rab11A in the cell, for example to treat or prevent a pathogen infection. Exemplary pathogens are those that use a lipid raft. The disclosure also relates to methods of identifying agents involved in pathogen infection, such as modulators of Rab9A and Rab11A.



WO 2005/092924 A3